Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
Yasunori Murata(Ichinomiya Kenshin College), Nobuhiko Seki(Teikyo University), Satoshi Watanabe(Niigata University Medical and Dental Hospital), Anna Hayashi(Nippon Medical School), Kosuke Tsuruno(Aso Iizuka Hospital), Kazuhiro Asada(Shizuoka General Hospital), Kiichiro Ninomiya(Okayama Shoka University), Hiroshi Kuraishi(Nagano Red Cross Hospital), Hisashi Tanaka(Hirosaki University), Eisaku Miyauchi(Tohoku University), Akira Nakao(Hiroshima University), Kakuhiro Yamaguchi(Hiroshima University Hospital), Teppei Yamaguchi(Aichi Cancer Center), Toshihiro Misumi(Yokohama City University), Hiroshi Tanaka(Hachinohe Gakuin University), Hiroshige Yoshioka(Harbin Medical University), Satoshi Tetsumoto(Suita Municipal Hospital), Yosuke Kawashima(Sendai Kousei Hospital), Ken Yoshihara(Shimane University), Shigeru Tanzawa(Teikyo University), Akihito Kubo(Aichi Medical University), Yuki Misumi(Yokohama Municipal Citizen's Hospital), Akihiko Miyanaga(Nippon Medical School), Toshihiko Yokoyama(Japanese Red Cross Nagoya Daiichi Hospital), Shoichi Kuyama(Iwakuni Medical Center), Yuki Sato(Kobe City Medical Center General Hospital), Yukihiro Umeda(University of Fukui), Toshiyuki Kozuki(Shikoku Cancer Center), Shunichi Sugawara(Sendai Kousei Hospital), Masafumi Nojiri(Kanazawa Medical University), Kazuki Hashimoto(Toneyama National Hospital), Akito Hata, Kensaku Ito(National Hospital Organization Kyushu Cancer Center), Takuji Suzuki(Chiba University), Ryoichi Honda(Asahi General Hospital), Masahide Mori(Toneyama National Hospital), Ken Masuda(Hiroshima City Asa Citizens Hospital), Kana Watanabe(Miyagi Prefectural Hospital Organization), Takahisa Kawamura(Osaka International Cancer Institute), Masafumi Takeshita, Tatsuro Okamoto(National Hospital Organization Kyushu Cancer Center)
Cited by 5
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695